n-Lorem Foundation

n-Lorem is at the forefront of treating and learning from nano-rare patients. Join Stanley Crooke, M.D., Ph.D., Founder, Chairman, and CEO of n-Lorem, as he details just how n-Lorem is delivering hope for a brighter future, one nano-rare patient at a time. The 2024 Nano-Rare Patient Colloquium begins this Wednesday, October 30 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ  

Nano-rare Patient Colloquium 2024 is just around the corner! Hongene is proud to support n-Lorem Foundation in its mission to provide personalized experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients – for free, for life! Join us with the community of care to share experiences, important lessons, and insights that will reshape how we think about health and disease! Register now: https://lnkd.in/gv4AQGjQ #NRPC24 #raredisease #ASO #oligonucleotides #RNAtherapeutics

n-Lorem is gathering essential insights from a wide variety of submitted applications. Our clinical processes facilitate the industrialization of personalized ASOs, while our expanding clinical data offers valuable perspectives on the effects of ASO treatment. Join Laurence Mignon, Ph.D., our Executive Director of Clinical Development, as she outlines how n-Lorem's clinical experiences are shaping the future of personalized ASO medicines. The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ 

The challenges presented by nano-rare patients are far too complex for n-Lorem to solve even a fraction of them without support. Thus, our goal from inception has been to build as broad and effective a network of contributing stakeholders as possible. In this panel, our partners in the community of care discuss what it means to partner with n-Lorem, including how this partnership provides their employees with a sense of pride and what more their organizations can do to support nano-rare patients. The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ  

At n-Lorem, every nonclinical process—ranging from the formation of various committees to ASO design and discovery, regulatory activities, and beyond—is vital for effectively treating nano-rare patients. Join Julie Douville, Ph.D., our Executive Director of ASO Discovery and Development, as she explores n-Lorem's nonclinical processes and explains how they lead to successful patient treatments and support the industrialization of personalized ASO medicines. The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ 

n-Lorem exists to serve the nano-rare patient community. The opportunity for ASO treatment offers hope to those who feel hopeless and, ultimately, we aspire to provide treatments for many. The despair and hopelessness experienced at the end of a long and perilous journey to diagnosis can be devastating, yet the possibility of potential help is truly uplifting. In this special panel, some of our nano-rare patient families will share their diagnostic odysseys and discuss what n-Lorem means to them.  The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ 

Pioneers like Susannah and Sloane are paving a pathway for more nano-rare patients, providing valuable information on health and disease and experiencing, for the first time, targeted therapeutic intervention for their genetic conditions. Join us as Susannah's Father, Luke Rosen, Sloane’s Mother, Megan Hedstrom, and their dedicated physician, Jennifer Bain, M.D., Ph.D., talk with Features Editor of the Transmitter, Brady Huggett, to share their children’s KIF1A diagnostic journeys and unique clinical experiences.  The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ 

We're just one week away from the 2024 Nano-rare Patient Colloquium! If you're attending in person, don't miss the reception, generously sponsored by Hongene Biotech Corporation, on October 30 after Day 1. Enjoy an evening of mingling over small bites and drinks, connect with community members, engage in meaningful conversations, and bid on art created by n-Lorem patients. We look forward to warmly welcoming you at the Boston Marriott Cambridge. See you there!

n-Lorem benefits from over 35 years of ASO expertise and leverages ongoing research innovation to ensure that every patient receives the most effective ASO treatment possible. Join Konstantina Skourti-Stathaki, PhD, our Director of ASO Design and Discovery, as she provides insights into the activities happening in the n-Lorem lab, discusses the active research we are conducting to drive advancements in ASO technology, and outlines our ASO design and discovery process. The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ 

n-Lorem is developing a promising solution for nano-rare patients through the industrialization of personalized ASO medicines, establishing an infrastructure that seamlessly integrates expertise and processes. Join Sarah Glass, PhD Glass, Ph.D., our Chief Operating Officer, as she shares how n-Lorem is turning what once seemed impossible into reality by creating a scalable approach to treat nano-rare patients. The 2024 Nano-Rare Patient Colloquium is October 30-31 in Cambridge, MA. Register to attend in person or virtually here: https://lnkd.in/gv4AQGjQ